210 related articles for article (PubMed ID: 33208671)
61. Genetic Characteristics of Colorectal Neuroendocrine Carcinoma: More Similar to Colorectal Adenocarcinoma.
Chen L; Liu M; Zhang Y; Guo Y; Chen MH; Chen J
Clin Colorectal Cancer; 2021 Jun; 20(2):177-185.e13. PubMed ID: 33041225
[TBL] [Abstract][Full Text] [Related]
62. Delta-like 3 localizes to neuroendocrine cells and plays a pivotal role in gastrointestinal neuroendocrine malignancy.
Matsuo K; Taniguchi K; Hamamoto H; Ito Y; Futaki S; Inomata Y; Shima T; Asakuma M; Lee SW; Tanaka K; Okuda J; Kondo Y; Uchiyama K
Cancer Sci; 2019 Oct; 110(10):3122-3131. PubMed ID: 31369178
[TBL] [Abstract][Full Text] [Related]
63. Extrapulmonary poorly differentiated NECs, including molecular and immune aspects.
McNamara MG; Scoazec JY; Walter T
Endocr Relat Cancer; 2020 Jul; 27(7):R219-R238. PubMed ID: 32357308
[TBL] [Abstract][Full Text] [Related]
64. TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix.
Tornesello ML; Annunziata C; Buonaguro L; Losito S; Greggi S; Buonaguro FM
J Transl Med; 2014 Sep; 12():255. PubMed ID: 25220666
[TBL] [Abstract][Full Text] [Related]
65. Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
Lee HK; Kwon MJ; Ra YJ; Lee HS; Kim HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Min KW; Kang SY
Diagn Pathol; 2020 Oct; 15(1):126. PubMed ID: 33054840
[TBL] [Abstract][Full Text] [Related]
66. PD-L1 Expression in Small Cell and Large Cell Neuroendocrine Carcinomas of Lung: an Immunohistochemical Study with Review of Literature.
Guleria P; Kumar S; Malik PS; Jain D
Pathol Oncol Res; 2020 Oct; 26(4):2363-2370. PubMed ID: 32506394
[TBL] [Abstract][Full Text] [Related]
67. Comprehensive analysis of mutational and clinicopathologic characteristics of poorly differentiated colorectal neuroendocrine carcinomas.
Lee SM; Sung CO
Sci Rep; 2021 Mar; 11(1):6203. PubMed ID: 33737597
[TBL] [Abstract][Full Text] [Related]
68. H-ras and Nm23-H1 gene expression and proteolytic activity in squamous cell carcinoma of the uterine cervix.
Utrera-Barillas D; Salcedo-Vargas M; Gariglio-Vidal P; Hernández-Hernández DM; Gutiérrez-Delgado F; Benítez-Bribiesca L
Arch Med Res; 2000; 31(2):172-81. PubMed ID: 10880723
[TBL] [Abstract][Full Text] [Related]
69. Establishment, functional and genetic characterization of a colon derived large cell neuroendocrine carcinoma cell line.
Gock M; Mullins CS; Harnack C; Prall F; Ramer R; Göder A; Krämer OH; Klar E; Linnebacher M
World J Gastroenterol; 2018 Sep; 24(33):3749-3759. PubMed ID: 30197480
[TBL] [Abstract][Full Text] [Related]
70. Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications.
Wolkow N; Jakobiec FA; Afrogheh AH; Eagle RC; Pai SI; Faquin WC
Am J Ophthalmol; 2019 Apr; 200():226-241. PubMed ID: 30633894
[TBL] [Abstract][Full Text] [Related]
71. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
72. Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia.
Curley J; Conaway MR; Chinn Z; Duska L; Stoler M; Mills AM
Mod Pathol; 2020 Jun; 33(6):1182-1192. PubMed ID: 32139873
[TBL] [Abstract][Full Text] [Related]
73. Molecular characterization of cancers with NTRK gene fusions.
Gatalica Z; Xiu J; Swensen J; Vranic S
Mod Pathol; 2019 Jan; 32(1):147-153. PubMed ID: 30171197
[TBL] [Abstract][Full Text] [Related]
74. Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.
Mirkovic J; McFarland M; Garcia E; Sholl LM; Lindeman N; MacConaill L; Dong F; Hirsch M; Nucci MR; Quick CM; Crum CP; McCluggage WG; Howitt BE
Am J Surg Pathol; 2018 Feb; 42(2):227-233. PubMed ID: 28984674
[TBL] [Abstract][Full Text] [Related]
75. Spectrum of neuroendocrine carcinomas of the uterine cervix, including histopathologic features, terminology, immunohistochemical profile, and clinical outcomes in a series of 50 cases from a single institution in India.
Rekhi B; Patil B; Deodhar KK; Maheshwari A; A Kerkar R; Gupta S; Tongaonkar HB; Shrivastava SK
Ann Diagn Pathol; 2013 Feb; 17(1):1-9. PubMed ID: 22534245
[TBL] [Abstract][Full Text] [Related]
76. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
77. Genomic characterization of small cell carcinomas of the uterine cervix.
Schultheis AM; de Bruijn I; Selenica P; Macedo GS; da Silva EM; Piscuoglio S; Jungbluth AA; Park KJ; Klimstra DS; Wardelmann E; Hartmann W; Gerharz CD; von Petersdorff M; Buettner R; Reis-Filho JS; Weigelt B
Mol Oncol; 2022 Feb; 16(4):833-845. PubMed ID: 33830625
[TBL] [Abstract][Full Text] [Related]
78. Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.
Reis H; van der Vos KE; Niedworok C; Herold T; Módos O; Szendrői A; Hager T; Ingenwerth M; Vis DJ; Behrendt MA; de Jong J; van der Heijden MS; Peyronnet B; Mathieu R; Wiesweg M; Ablat J; Okon K; Tolkach Y; Keresztes D; Nagy N; Bremmer F; Gaisa NT; Chlosta P; Kriegsmann J; Kovalszky I; Timar J; Kristiansen G; Radzun HJ; Knüchel R; Schuler M; Black PC; Rübben H; Hadaschik BA; Schmid KW; van Rhijn BWG; Nyirády P; Szarvas T
Int J Cancer; 2018 Oct; 143(7):1764-1773. PubMed ID: 29672836
[TBL] [Abstract][Full Text] [Related]
79. Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung.
Miyoshi T; Umemura S; Matsumura Y; Mimaki S; Tada S; Makinoshima H; Ishii G; Udagawa H; Matsumoto S; Yoh K; Niho S; Ohmatsu H; Aokage K; Hishida T; Yoshida J; Nagai K; Goto K; Tsuboi M; Tsuchihara K
Clin Cancer Res; 2017 Feb; 23(3):757-765. PubMed ID: 27507618
[TBL] [Abstract][Full Text] [Related]
80. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
